PMID- 27441746
OWN - NLM
STAT- MEDLINE
DCOM- 20170822
LR  - 20220409
IS  - 1540-336X (Electronic)
IS  - 1528-9117 (Print)
IS  - 1528-9117 (Linking)
VI  - 22
IP  - 4
DP  - 2016 Jul-Aug
TI  - Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy 
      (SBRT) Era.
PG  - 267-73
LID - 10.1097/PPO.0000000000000203 [doi]
AB  - Stereotactic body radiation therapy (SBRT) utilizing a small number of high-dose 
      radiation therapy fractions continues to expand in clinical application. Although 
      many approaches have been proposed to radiosensitize tumors with conventional 
      fractionation, how these radiosensitizers will translate to SBRT remains largely 
      unknown. Here, we review our current understanding of how SBRT eradicates tumors, 
      including the potential contributions of endothelial cell death and immune system 
      activation. In addition, we identify several new opportunities for 
      radiosensitization generated by the move toward high dose per fraction radiation 
      therapy.
FAU - Moding, Everett J
AU  - Moding EJ
AD  - From the *Department of Radiation Oncology, Duke University, Durham; daggerDepartment 
      of Internal Medicine, Moses H. Cone Memorial Hospital, Greensboro; and 
      double daggerDepartment of Pharmacology & Cancer Biology, Duke University, Durham, NC.
FAU - Mowery, Yvonne M
AU  - Mowery YM
FAU - Kirsch, David G
AU  - Kirsch DG
LA  - eng
GR  - K02 AI093866/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cancer J
JT  - Cancer journal (Sudbury, Mass.)
JID - 100931981
SB  - IM
MH  - Humans
MH  - Immunosuppression Therapy/methods
MH  - Immunotherapy/*methods
MH  - Neoplasms/immunology/radiotherapy/*therapy
MH  - Radiation Tolerance
MH  - Radiosurgery/*methods
PMC - PMC4957656
MID - NIHMS786466
EDAT- 2016/07/22 06:00
MHDA- 2017/08/23 06:00
PMCR- 2017/07/01
CRDT- 2016/07/22 06:00
PHST- 2016/07/22 06:00 [entrez]
PHST- 2016/07/22 06:00 [pubmed]
PHST- 2017/08/23 06:00 [medline]
PHST- 2017/07/01 00:00 [pmc-release]
AID - 00130404-201607000-00006 [pii]
AID - 10.1097/PPO.0000000000000203 [doi]
PST - ppublish
SO  - Cancer J. 2016 Jul-Aug;22(4):267-73. doi: 10.1097/PPO.0000000000000203.